The bill amends sections 3902.50 and 3902.70 of the Revised Code and enacts a new section 3902.72, which prohibits drug manufacturers from engaging in certain actions regarding the acquisition and delivery of drugs to 340B covered entities. Specifically, it prevents manufacturers, repackagers, and third-party logistics providers from denying or limiting the acquisition of 340B drugs by these entities, as well as from requiring them to submit claims or utilization data as a condition for drug acquisition. The bill also establishes definitions for terms related to the 340B drug pricing program and outlines penalties for violations, including civil penalties and potential referral to the state board of pharmacy.

Additionally, the bill includes provisions that require health plan issuers and pharmacy benefit managers to provide timely and accurate data regarding drug coverage and cost-sharing to covered persons and their healthcare providers. This includes ensuring that the data is current, provided in real-time, and accessible regardless of how the request is made. The bill aims to enhance transparency and access to information for patients and healthcare providers while ensuring compliance with federal regulations. Existing sections 3902.50, 3902.70, and 3902.72 are repealed as part of this legislative update.

Statutes affected:
As Introduced: 3902.50, 3902.70, 3902.72, 3902.75